Soleno Therapeutics, Inc.
Securities Class Action
Company Name: Soleno Therapeutics, Inc. (SLNO)
Download ComplaintMarch 26, 2025 - November 4, 2025
May 5, 2026|7 days left
Please submit the form below if you believe you have incurred losses.
Thank you. We will be in touch with you shortly.
By clicking the submit button above, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Pomerantz LLP ("Pomerantz" or "The Firm"), and that the submission or receipt of information to the Firm or one of its attorneys via this form, website, e-mail or telephone does not create an attorney-client relationship. Prior results do not guarantee a similar outcome in future cases.
Pomerantz LLP does not share your information with others. There is no cost or obligation for you to submit. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases.
Allegations
On August 15, 2025, Scorpion Capital (“Scorpion”) published a report that described Soleno’s only product, diazoxide choline extended-release tablets (“DCCR”), as overpriced and potentially unsafe for children. Following publication of the Scorpion report, Soleno’s stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025. Then, on September 10, 2025, Soleno disclosed in a filing with the U.S. Securities and Exchange Commission that a patient had died after taking DCCR. On this news, Soleno’s stock price fell $13.49 per share, or 19.21%, over the following two trading sessions, to close at $56.72 per share on September 11, 2026. Finally, on November 4, 2025, Soleno revealed during its quarterly earnings call that the discontinuation rate of DCCR related to adverse effects was approximately 8% at the end of the third quarter of fiscal 2025. Soleno’s Chief Executive Officer said during the call that the Scorpion report had caused a “disruption” in DCCR’s launch trajectory, with a lower number of patient start forms and increased discontinuations beginning after the report’s publication. On this news, Soleno’s stock price fell $16.98 per share, or 26.59%, to close at $46.87 per share on November 5, 2025.
Lead Plaintiff
If you have qualifying losses, you may be eligible to serve as Lead Plaintiff. Acting as a representative for all class members seeking recovery in the lawsuit, the Lead Plaintiff plays an important role in the litigation, including selecting a law firm to serve as Lead Counsel and approving the final settlement. There is no cost whatsoever to seek or participate as a Lead Plaintiff. The Lead Plaintiff may also receive a monetary award for their participation in the suit.
About the Firm
Founded in 1936, Pomerantz LLP is the oldest law firm in the world dedicated to championing investor rights. Throughout its history, the Firm has won landmark decisions that have initiated historic corporate governance reforms and shaped the law to better protect shareholders. Pomerantz has successfully resolved hundreds of securities class actions as Lead Counsel, recovering billions of dollars on behalf of defrauded investors with many settlements breaking previously held records. Pomerantz is headquartered in New York City, with offices in Los Angeles, Chicago, Paris, London, and Tel Aviv.